Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) reported that its lead drug formulation Rudivar has been shown to be more effective than the currently approved standard of care drug Acyclovir in destroying Herpes Simplex Virus 1 (HSV-1) in a preclinical setting.
The latest research carried out at the University of Manitoba demonstrated that Rudivar is more potent than Acyclovir, which does not cure herpes but can lessen the symptoms of the infection.
The company highlighted that Acyclovir was not able to prevent HSV-1 replication if added one day after infection, but Rudivar was able to prevent HSV-1 replication by 10 million-fold when added one day after infection.
This means that if a patient has pre-existing HSV-1, Acyclovir would be unable to prevent the replication of the virus but Rudivar would be “extremely effective.”
“This latest research continues to strengthen what we already know, Ruvidar is a very potent drug in the destruction of cancer, viruses and bacteria on its own and is further enhanced by light, radiation, sound or drug activation,” Theralase CEO Roger DuMoulin-White commented.
“Based on this latest research, Theralase plans to commence seeking a partner/licensing opportunity in the development of Ruvidar for both a topical and oral treatment for the prevention and treatment of herpes simplex.”